Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Pelosi Flags Poison Pills in Stimulus Talks; Testing Deal Nears

Published 10/16/2020, 10:35 PM
Updated 10/16/2020, 10:54 PM
Pelosi Flags Poison Pills in Stimulus Talks; Testing Deal Nears

(Bloomberg) -- House Speaker Nancy Pelosi told Democratic colleagues that a divide persists with the White House over a number of components of the fiscal stimulus she’s attempting to negotiate, even as an agreement nears on a coronavirus testing program.

The establishment of a national testing strategy had been a roadblock cited by Pelosi and her aides this week during talks with Treasury Secretary Steven Mnuchin.

After a call lasting more than an hour Thursday, Mnuchin said the administration would only make minor edits to a Democratic proposal on that score. Paperwork is expected to be exchanged on Friday.

“Many other disagreements remain,” Pelosi wrote in a letter to colleagues Thursday evening. “These include but are not limited to funding for state and local government, tax benefits for working families, support for vulnerable small businesses, and child care funding.”

She also cited multiple so-called poison pills, “including their radical Liability Provision which forces workers to risk their lives in unsafe workplaces with no legal recourse.” Senate Majority Leader Mitch McConnell has been a strong advocate for liability protections for businesses to shield them from coronavirus-related lawsuits as they reopen.

McConnell has raised his own major roadblock to any deal: the size. President Donald Trump said Thursday he was prepared to go beyond the $1.8 trillion his team had been trying to offer to Pelosi, who favors a $2.2 trillion plan.

Republican Roadblock

“He’s talking about a much larger amount than I can sell to my members,” McConnell said Thursday of Trump’s latest position.

The Treasury chief told Pelosi that Trump would weigh in with McConnell if an agreement were reached. Trump himself said of the Senate Republicans, “They’ll go. I haven’t asked them” because there isn’t a deal yet.

Mnuchin is expected to head to the Middle East in coming days, adding to signs that a pre-election agreement on stimulus won’t be forthcoming -- though both sides have pledged to keep working on it.

Details of the emerging testing agreement haven’t been released. Pelosi and House Democrats have demanded $75 billion for what they’ve described as “a science-based national plan for testing, tracing, treatment and isolation, and for the equitable and ethical distribution of a safe and effective vaccine once developed.”

©2020 Bloomberg L.P.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.